Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 22nd May 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 6, 2005
Previous Article Next Article

Natural products to drugs: daptomycin and related lipopeptide antibiotics

Author affiliations

Abstract

Covering: 1953 to September 2005

Daptomycin (Cubicin®) is a lipopeptide antibiotic approved in the USA in 2003 for the treatment of skin and skin structure infections caused by Gram-positive pathogens. It is a member of the 10-membered cyclic lipopeptide family of antibiotics that includes A54145, calcium-dependent antibiotic (CDA), amphomycin, friulimicin, laspartomycin, and others. This review highlights research on this class of antibiotics from 1953 to 2005, focusing on more recent studies with particular emphasis on the interplay between structural features and antibacterial activities; chemical modifications to improve activity; the genetic organization and biosynthesis of lipopeptides; and the genetic engineering of the daptomycin biosynthetic pathway to produce novel derivatives for further chemical modification to develop candidates for clinical evaluation.

Graphical abstract: Natural products to drugs: daptomycin and related lipopeptide antibiotics

Back to tab navigation

Publication details

The article was received on 28 Sep 2005 and first published on 04 Nov 2005


Article type: Review Article
DOI: 10.1039/B416648P
Nat. Prod. Rep., 2005,22, 717-741

  •   Request permissions

    Natural products to drugs: daptomycin and related lipopeptide antibiotics

    R. H. Baltz, V. Miao and S. K. Wrigley, Nat. Prod. Rep., 2005, 22, 717
    DOI: 10.1039/B416648P

Search articles by author

Spotlight

Advertisements